31 Dec 2025 For shareholders of Novo Nordisk (NVO) , the past three years have been a masterclass in value creation. High margins, infinite demand, and a virtual monopoly in the obesity market drove the stock to record highs.Read more
Business Overview Total: 8.5/17 +2 ✅✅ Projected Operating Margin: 43.88% +1 ✅ Projected 5-Year Revenue CAGR: 11.93% +2 ✅✅ Last 5-Year ROIC: 54.60% +1 ✅ Estimated Cost of Capital: 7.54% (lower than ROIC) +1 ✅ Last 5-Year Shares Outstanding CAGR: -0.89% -1 ❌ Projected 5-Year EPS CAGR: 8.49% (given the easiness that the companies have in manipulating these numbers, below 10% represents a negative) +0 ⚠️ Projected 5-Year Dividend CAGR: 6.45% +1.5 ✅ Estimated Debt Rating: Aa3 +2 ✅✅ Morningstar Moat: Wide -1 ❌ Morningstar Uncertainty: High Novo Nordisk is the leader in obesity and diabetes treatments. Its wide moat is reflected on its stellar operating margin.Read more
Novo Nordisk, one of the world’s leading pharmaceutical companies, has a unique and inspiring origin story rooted in personal tragedy and scientific curiosity. The company’s roots date back to the 1920s, when Danish Nobel laureate August Krogh, a renowned physiologist, and his wife Marie, who suffered from type 2 diabetes, traveled to Canada.Read more
Catalysts Most Immediate Catalyst (1–2 Years): Weight-Loss Drug Boom: Novo Nordisk’s Wegovy (semaglutide) is dominating the obesity drug market , with demand outpacing supply. Obesity treatment is becoming a major new revenue stream.Read more
Key Takeaways International expansion and supply ramp-up position the company for robust, sustained growth by unlocking untapped patient pools and converting demand into profit. Innovation in pipeline, digital health leadership, and streamlined operations broaden revenue streams and boost efficiency, strengthening dominance in chronic disease management.Read more
Key Takeaways Vast global demand for GLP-1 therapies and metabolic disease treatments offers long-term revenue growth, as adoption and access increase amid rising obesity and aging trends. Expanded product launches, manufacturing investments, and innovation in new disease areas are set to boost market reach, support resilient earnings, and reduce supply constraints.Read more
Key Takeaways Heavy reliance on blockbuster therapies and looming patent expirations expose Novo Nordisk to revenue pressure from biosimilar competition and pricing headwinds. Expanding international demand is offset by rising economic inequality, regulatory risks, and escalating operating costs, threatening long-term growth and margins.Read more
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
